Prevention of Contrast Induced Nephropathy by Erythropoietin

Status Recruiting

Clinical Trial Summary

This ia a prospective, randomized, double blind, placebo controlled trial. patients schedule for primary PCI or elective PCI will randomly allocated to receive either a single dose of EPO (Recormon, Roche, Epoetin beta) or saline intravenously before PCI.

The investigators assume that the incidence rate of CIN will be significantly lower in the EPO group compared to placebo. In addition, EPO administration will result in a decrease of infarct size.

Clinical Trial Description

Radiological procedures utilizing intravascular contrast media are being widely applied for both diagnostic and therapeutic purposes. This has resulted in the increasing incidence of procedure-related contrast-induced nephropathy (CIN), which was found to be associated with poor outcome including higher in-hospital mortality rates. Therefore, finding ways to prevent CIN is a valuable clinical and research goal. However, there are no current methods for efficient and cost-effective prevention CIN. Erythropoietin (EPO) has been shown to elicit tissue-protective effects in various experimental models and few clinical studies of acute kidney injury (AKI). Therefore, this prospective, randomized, double blind, placebo controlled trial aim to evaluate, for the first time, the effectiveness of EPO in the prevention of CIN after percutaneous coronary intervention (PCI).

The potential reno-protective effect of EPO is expected to reduce the incidence of the third leading cause of hospital-acquired acute kidney injury. The above together with a cardio-protective effect of EPO is expected to reduce patient's morbidity, mortality and the high health cost associated with CIN treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01364402
Study type	Interventional
Source	Western Galilee Hospital-Nahariya
Contact	Lilach Shema-Didi, RN, MPH
Phone	972-507887538
Email	lilach_01@yahoo.com
Status	Recruiting
Phase	Phase 3
Start date	August 2011
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05594446` - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed	`NCT03975309` - DHS MIND Metabolomics
Completed	`NCT01855399` - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes	N/A
Completed	`NCT01819129` - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes	Phase 3
Recruiting	`NCT04984226` - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD	Phase 2
Recruiting	`NCT05007990` - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting	`NCT04420936` - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program	N/A
Recruiting	`NCT03549559` - Imaging Histone Deacetylase in the Heart	N/A
Completed	`NCT04903496` - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed	`NCT01437592` - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects	Phase 1
Completed	`NCT01696266` - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed	`NCT04082585` - Total Health Improvement Program Research Project
Completed	`NCT03390179` - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting	`NCT05029804` - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes	N/A
Recruiting	`NCT05294822` - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes	N/A
Completed	`NCT04427982` - Dance and Diabetes/Prediabetes Self-Management	N/A
Completed	`NCT02356848` - STEP UP to Avert Amputation in Diabetes	N/A
Completed	`NCT03292185` - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects	Phase 1
Active, not recruiting	`NCT05477368` - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes	N/A
Completed	`NCT04496401` - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.